191 related articles for article (PubMed ID: 33268029)
1. Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma.
Tschan-Plessl A; Kalberer CP; Wieboldt R; Stern M; Siegler U; Wodnar-Filipowicz A; Gerull S; Halter J; Heim D; Tichelli A; Tsakiris DA; Malmberg KJ; Passweg JR; Bottos A
Cytotherapy; 2021 Apr; 23(4):329-338. PubMed ID: 33268029
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.
Klingemann H; Grodman C; Cutler E; Duque M; Kadidlo D; Klein AK; Sprague KA; Miller KB; Comenzo RL; Kewalramani T; Yu N; Van Etten RA; McKenna DH
Transfusion; 2013 Feb; 53(2):412-8; quiz 411. PubMed ID: 22738379
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
4. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma.
Nieto Y; Banerjee P; Kaur I; Kim KH; Fang D; Thall PF; Griffin L; Barnett M; Basar R; Hosing C; Ramdial J; Srour S; Daher M; Marin D; Jiang X; Chen K; Champlin R; Shpall EJ; Rezvani K
Transplant Cell Ther; 2024 Feb; 30(2):203.e1-203.e9. PubMed ID: 38042257
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of cord blood-derived natural killer cells as maintenance therapy after autologous hematopoietic stem cell transplantation.
Wu Y; Wang Y; Ji J; Kuang P; Chen X; Liu Z; Li J; Dong T; Li X; Chen Q; Liu T
Ann Hematol; 2023 Nov; 102(11):3229-3237. PubMed ID: 37775597
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
[TBL] [Abstract][Full Text] [Related]
9. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Shah N; Li L; McCarty J; Kaur I; Yvon E; Shaim H; Muftuoglu M; Liu E; Orlowski RZ; Cooper L; Lee D; Parmar S; Cao K; Sobieiski C; Saliba R; Hosing C; Ahmed S; Nieto Y; Bashir Q; Patel K; Bollard C; Qazilbash M; Champlin R; Rezvani K; Shpall EJ
Br J Haematol; 2017 May; 177(3):457-466. PubMed ID: 28295190
[TBL] [Abstract][Full Text] [Related]
11. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma.
Nahi H; Chrobok M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Blomberg P; Holmqvist PH; Walther-Jallow L; Mellström K; Liwing J; Gustafsson C; Månsson R; Klimkowska M; Gahrton G; Lund J; Ljungman P; Ljunggren HG; Alici E
Cell Rep Med; 2022 Feb; 3(2):100508. PubMed ID: 35243416
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
13. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Cook G; Williams C; Brown JM; Cairns DA; Cavenagh J; Snowden JA; Ashcroft AJ; Fletcher M; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Chalmers A; O'Connor S; Drayson MT; Morris TC;
Lancet Oncol; 2014 Jul; 15(8):874-85. PubMed ID: 24948586
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
Coffey DG; Osman K; Aleman A; Bekri S; Kats S; Dhadwal A; Catamero D; Kim-Schulze S; Gnjatic S; Chari A; Parekh S; Jagannath S; Cho HJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609316
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S; Lapteva N; Garg T; Greenway A; Lingo J; Nair B; Stone K; Woods E; Khan J; Stivers J; Panozzo S; Campana D; Bellamy WT; Robbins M; Epstein J; Yaccoby S; Waheed S; Gee A; Cottler-Fox M; Rooney C; Barlogie B; van Rhee F
J Immunother; 2015 Jan; 38(1):24-36. PubMed ID: 25415285
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
18. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
19. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
20. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
